SLM reports consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca, and Pfizer; is an investigator on clinical trials for Sanofi, GSK, and Sparrow; speaking or lecturing on behalf of her institution for Roche/Chugai, Vifor, Pfizer, UCB, and Novartis; is chief investigator on the STERLING-PMR trial, funded by National Institute for Health and Care Research (NIHR); and is patron of the charity PMRGCAuk. No personal remuneration was received for any of the mentioned activities. SLM reports support from Roche/Chugai to attend the Annual European Congress of Rheumatology 2019 in person and from Pfizer to attend the American College of Rheumatology Convergence 2021 virtually. TR declares no competing interests. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the NIHR Leeds Biomedical Research Centre, the National Health Service, or the UK Department of Health and Social Care.